Amanta Healthcare IPO Subscribed 6 Times by Day 2, GMP Dips to 12%

Amanta Healthcare’s Initial Public Offering (IPO), launched on September 1, 2025, has garnered significant attention in the financial markets. With a price band set between ₹120 and ₹126 per share, the IPO aims to raise ₹126 crore. By the second day of bidding, the issue was oversubscribed 12.40 times, primarily driven by strong demand from retail investors. However, the Grey Market Premium (GMP) has experienced a decline to 12%, indicating a shift in market sentiment.

About Amanta Healthcare

Amanta Healthcare is a pharmaceutical firm that focuses on producing, developing, and selling sterile liquid products, including large and small volume parenterals (LVPs and SVPs) and medical devices. Headquartered in Ahmedabad, India, the company has established a strong presence in the healthcare sector, focusing on quality and innovation. The proceeds from the IPO are intended to fund expansion plans and enhance the company’s financial standing.

IPO Details

• Issue Size: ₹126 crore
• Price Band: ₹120 to ₹126 per share
• Lot Size: 119 shares
• Subscription Dates: September 1 to September 3, 2025
• Listing Date: September 9, 2025 (tentative)
• Lead Manager: Beeline Capital Advisors Pvt. Ltd.
• Registrar: MUFG Intime India Pvt. Ltd.

Subscription Status and Investor Response

The Amanta Healthcare IPO has witnessed robust investor interest. By the second day of bidding, the issue was oversubscribed 12.40 times, with retail investors leading the demand. The Non-Institutional Investors (NIIs) have also shown significant participation, with their portion subscribed 16.47 times. This strong response indicates positive sentiment towards the company’s growth prospects in the pharmaceutical sector.

Grey Market Premium (GMP) Trends

The Grey Market Premium (GMP) for the Amanta Healthcare IPO has seen varying trends. At first, the GMP stood at ₹28, pointing to a possible listing price near ₹155, which represents a 22% premium over the upper price range. By day two, the GMP dropped to ₹12, showing a shift in how investors were feeling. This volatility underscores the importance of monitoring market dynamics when considering IPO investments.

Conclusion

The Amanta Healthcare IPO has attracted considerable attention, with strong subscription numbers and initial GMP indicating investor interest. However, the recent decline in GMP suggests a need for cautious evaluation. Potential investors should consider the company’s fundamentals, market conditions, and personal investment goals before participating. As always, conducting thorough research and consulting with financial advisors is recommended when making investment decisions.

Disclaimer:

This content is for informational purposes only and is not financial advice. Always conduct your research.